Thyroid cancer has one of the highest survival rates of any cancer. The overall 5-year relative survival rate for localized thyroid cancer is 99.9%, meaning nearly everyone diagnosed at this stage is alive five years later. But that number shifts significantly depending on the type of thyroid cancer, how far it has spread, and the patient’s age at diagnosis.
Survival Rates by Stage
Thyroid cancer survival depends heavily on whether the cancer has stayed in the thyroid, reached nearby lymph nodes, or spread to distant organs. Based on data from the National Cancer Institute’s SEER program (2016 to 2022), the 5-year relative survival rates break down as follows:
- Localized (confined to the thyroid): 99.9%
- Regional (spread to nearby lymph nodes): 98.1%
- Distant (spread to other organs): 48.3%
Most thyroid cancers are caught at the localized or regional stage, which explains why the overall prognosis is so favorable. Even when the cancer has spread to lymph nodes in the neck, the survival rate barely drops. The picture changes substantially with distant spread, but even then, nearly half of patients survive five years or more.
How Survival Differs by Type
Not all thyroid cancers behave the same way. There are four main types, and the differences in survival are dramatic. Papillary thyroid cancer, the most common type (accounting for roughly 80% of cases), has some of the best outcomes of any cancer. Follicular thyroid cancer, the second most common, is close behind. Medullary thyroid cancer is rarer and somewhat more aggressive. Anaplastic thyroid cancer is the outlier: rare but extremely aggressive.
Here’s how the 5-year survival rates compare, based on American Cancer Society data from patients diagnosed between 2015 and 2021:
Papillary thyroid cancer:
- Localized: greater than 99%
- Regional: 99%
- Distant: 71%
Follicular thyroid cancer:
- Localized: greater than 99%
- Regional: 97%
- Distant: 62%
Medullary thyroid cancer:
- Localized: greater than 99%
- Regional: 94%
- Distant: 50%
Anaplastic thyroid cancer:
- Localized: 45%
- Regional: 14%
- Distant: 5%
The contrast is stark. Papillary and follicular thyroid cancers, often grouped together as “differentiated” thyroid cancers, maintain excellent survival even when they’ve spread to lymph nodes. Anaplastic thyroid cancer, by contrast, has a poor prognosis at every stage. It accounts for only about 1 to 2% of thyroid cancers, but it grows and spreads rapidly.
Long-Term Outlook Beyond Five Years
Because thyroid cancer often strikes younger people and has such high short-term survival, many patients want to know what the 10- or 20-year picture looks like. The news is reassuring for the most common forms. Research published in Frontiers in Endocrinology tracked long-term outcomes for low-risk papillary thyroid cancer and found that 20-year survival rates remain above 95% for most patients, even those with small amounts of lymph node involvement.
For small papillary tumors (11 to 13mm) confined to the thyroid, the 20-year survival rate was 99.1%. When those same small tumors had spread to a few nearby lymph nodes, the 20-year rate was still 97.4%. Even slightly larger tumors (17 to 20mm) with more extensive lymph node involvement maintained a 20-year survival above 95%. These numbers help explain why some doctors now recommend active surveillance rather than immediate surgery for very small, low-risk papillary thyroid cancers.
What Affects Your Individual Prognosis
Stage and type matter most, but several other factors influence outcomes.
Age at Diagnosis
Age plays a significant role in thyroid cancer prognosis. The current staging system uses age 55 as a dividing line: patients diagnosed before 55 are automatically classified as lower stage, reflecting their better outcomes. Research from the Journal of the Korean Surgical Society found that patients younger than 35 had particularly favorable outcomes, even when they experienced locoregional recurrence. Patients older than about 62 to 63 had notably worse prognosis regardless of other tumor characteristics. The older group also tended to present with more aggressive features, including larger tumors and more lymph node involvement.
Where Distant Metastases Appear
For the minority of patients whose thyroid cancer spreads to distant organs, the specific location matters. Spread to the lungs carries a median survival of about 10 months, while spread to bone is somewhat better at around 23 months. Brain and liver metastases carry the worst prognosis, with median survival of 5 and 6 months respectively. The 5-year survival for patients with brain metastases was just 6%, compared to 25% for bone metastases. Patients with cancer in multiple distant sites fare worse than those with spread to a single organ.
Genetic Mutations
Certain genetic changes in thyroid tumors can signal a more aggressive course. Two mutations that doctors increasingly test for are BRAF V600E and TERT promoter mutations. On its own, the BRAF mutation (found in a large percentage of papillary thyroid cancers) doesn’t significantly worsen survival. But when both mutations are present together, the risk of recurrence jumps dramatically: patients with both mutations had a 10.4-fold higher risk of recurrence compared to those without them. These co-mutations also made tumors less responsive to radioactive iodine treatment, which is one of the main therapies used after surgery for differentiated thyroid cancers.
Treatment and Its Effect on Survival
The standard treatment for most thyroid cancers is surgery to remove part or all of the thyroid, often followed by radioactive iodine therapy for differentiated types. Radioactive iodine works by being absorbed specifically by thyroid cells, destroying any remaining cancer tissue. For intermediate-risk papillary thyroid cancer, a large meta-analysis of over 56,000 patients found that radioactive iodine therapy was associated with better overall survival compared to no post-surgical treatment. However, it did not significantly reduce the rate of structural recurrence, meaning the cancer coming back as a visible mass. This distinction matters: patients who receive radioactive iodine may live longer overall, but the treatment doesn’t necessarily prevent the cancer from returning.
For low-risk papillary cancers, treatment is becoming less aggressive over time. Very small tumors may be monitored with regular ultrasounds rather than operated on immediately. When surgery is performed, some patients with low-risk features may skip radioactive iodine entirely. After treatment, most patients take thyroid hormone replacement for life, which also helps suppress any remaining cancer cells.
For anaplastic thyroid cancer, treatment is more intensive and typically involves a combination of surgery, radiation, and chemotherapy, though outcomes remain poor. Newer targeted therapies are available for some patients with specific genetic mutations, offering additional options where traditional treatments have limited effectiveness.